<DOC>
	<DOCNO>NCT02980302</DOCNO>
	<brief_summary>According World Health Organization ( WHO ) , mental retardation ( MR ) define intelligence quotient ( IQ ) &lt; 70 touch 1 3 % general population . Profound mental retardation ( QI &lt; 25 ) , severe ( IQ : 25-40 ) moderate ( QI : 40-50 ) prevalence 0,3-0,5 % prevalence mild MR , define IQ 50 70 evaluate 1,5 % . The origin MR infectious , toxic , traumatic , genetic environmental . genetic cause MR gather number structure anomaly chromosome , genomic microreorganization , monogenic disease rarely non Mendelian-inherited anomaly like print epigenetic anomaly , mutation mitochondrial genome etc ... Genetic cause represent 50 % moderate severe , whereas environmental factor ( malnutrition , cultural deprivation , ... ) play important role mild MR . The main goal study get innovative tool ( neuronal distinction iPSC ) wil allow study functionnal impact mutation uppon gene probably involve MR like MYT1L . The main criterion associate characterisation tool trial study pluripotency iPSC obtain highlight mutation gene MYT1L iPSC . Neurons iPSC patient father du patient wille also morphologically characterise , also thank expression specifically neurals gene . Characteristics iPSC neuron d'iPSC MYT1L mutation compare among patient father , relation cell come two witness .</brief_summary>
	<brief_title>Development Tool `` iPSC `` Functional Study Mutations Responsible Mental Retardation</brief_title>
	<detailed_description />
	<mesh_term>Intellectual Disability</mesh_term>
	<criteria>Inclusion Criteria : Patient intellectual deficiency and/or associate sign receive chromosomic analysis CGHarray revealing variant unknown signification involvingone gene candidate mental retardation . Certificate genetic genetic counselling sign consent . Under 18 person may necessary intellectual deficiency often diagnose adult age . Number case limit preliminary study one patient show rare mutation MYT1L gene father ( asymptomatic carrier mutation ) study . Affiliation social security system Exclusion Criteria : Persons mentionned L11215 L11218 CSP ( protected person ) Persons suffer acute infection practice cutaneous biopsy local anesthesia . Persons show hemostasis disorder acquire induced Persons sous traitement antiagr√©gant anticoagulant Persons mutation th gene MYT1L</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mental retardation MR</keyword>
	<keyword>IQ</keyword>
	<keyword>Mutation</keyword>
	<keyword>Gene MYT1L</keyword>
</DOC>